https://www.biopharmawatch.com/news/WHWK/whitehawk-therapeutics-ptk7-adc-target-nsclc-wclc-2026 BiopharmaWatch en 2026-09-14T01:30:00.000Z Whitehawk Therapeutics Presents Real-World Analyses Supporting PTK7 as a Durable ADC Target in EGFR Wild-Type Non-Small Cell Lung Cancer at WCLC 2026 https://www.biopharmawatch.com/news/CGEM/zipalertinib-chemotherapy-nsclc-trial-results BiopharmaWatch en 2026-09-13T23:15:00.000Z Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer https://www.biopharmawatch.com/news/DFTX/definium-therapeutics-panorama-study-results BiopharmaWatch en 2026-09-13T21:00:00.000Z Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 https://www.biopharmawatch.com/news/SMMT/ivonescimab-monotherapy-significant-benefit-pembrolizumab BiopharmaWatch en 2026-09-13T11:00:00.000Z Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study Conducted in China